PARNF (Parnell Pharmaceuticals Holdings) 1-Year Share Buyback Ratio : 0.00% (As of Dec. 2018 )

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Parnell Pharmaceuticals Holdings's current 1-Year Share Buyback Ratio was 0.00%.

PARNF's 1-Year Share Buyback Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -1.7
* Ranked among companies with meaningful 1-Year Share Buyback Ratio only.

Competitive Comparison of Parnell Pharmaceuticals Holdings's 1-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's 1-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Parnell Pharmaceuticals Holdings 1-Year Share Buyback Ratio Calculation

Parnell Pharmaceuticals Holdings's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2018 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2017 )	-	Shares Outstanding (EOP) (Dec. 2018 ))	/	Shares Outstanding (EOP) (Dec. 2017 )
	=	(18.028	-	18.024)	/	18.028
	=	0.0%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Parnell Pharmaceuticals Holdings 1-Year Share Buyback Ratio Related Terms

Parnell Pharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.